Chemical constituents from Cicuta virosa Linnaeus and their reversal effects on doxorubicin-resistant human myelogenous leukemia (K562/A02) cells

Wang, Shuqi; Zhang, Qingwei; Wang, Xiaoling; Di, Xiaxia; Wang, Xiaoning; Lou, Hongxiang

doi:10.1016/j.cclet.2016.03.039

Cited by 3 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…K562 cell line: 0.41 ± 0.20 mmol/L 2. K562/A02 cell line: 42.7 ± 0.14 mmol/L (b) reversal fold (RF) on K562/A02 =IC50 of cytotoxic DOX alone/IC50 of cytotoxic DOX: 0.97 (Wang et al, 2016) The marrow cavity of cortical bone (tuberosity region of the lower part of the tibia) of nude rats was injected with UMR-106 cells (rat osteosarcoma)…”

Section: In Vivo Experimentsmentioning

confidence: 99%

“…This is certainly an interesting area to look into as inhibition of microtubules can affect the cell proliferation of cancer cells (Jordan and Wilson, 2004). Angelicin had also been tested for its ability to reverse multidrug resistance in resistant human myelogenous leukemia (K562/A02) cell line but the results were not significant (Wang et al, 2016).…”

Section: North America and Chinamentioning

confidence: 99%

See 1 more Smart Citation

Angelicin—A Furocoumarin Compound With Vast Biological Potential

et al. 2020

View full text Add to dashboard Cite

Angelicin, a member of the furocoumarin group, is related to psoralen which is well known for its effectiveness in phototherapy. The furocoumarins as a group have been studied since the 1950s but only recently has angelicin begun to come into its own as the subject of several biological studies. Angelicin has demonstrated anti-cancer properties against multiple cell lines, exerting effects via both the intrinsic and extrinsic apoptotic pathways, and also demonstrated an ability to inhibit tubulin polymerization to a higher degree than psoralen. Besides that, angelicin too demonstrated anti-inflammatory activity in inflammatory-related respiratory and neurodegenerative ailments via the activation of NF-kB pathway. Angelicin also showed pro-osteogenesis and pro-chondrogenic effects on osteoblasts and pre-chondrocytes respectively. The elevated expression of proosteogenic and chondrogenic markers and activation of TGF-b/BMP, Wnt/b-catenin pathway confirms the positive effect of angelicin bone remodeling. Angelicin also increased the expression of estrogen receptor alpha (ERa) in osteogenesis. Other bioactivities, such as anti-viral and erythroid differentiating properties of angelicin, were also reported by several researchers with the latter even displaying an even greater aptitude as compared to the commonly prescribed drug, hydroxyurea, which is currently on the market. Apart from that, recently, a new application for angelicin against periodontitis had been studied, where reduction of bone loss was indirectly caused by its anti-microbial properties. All in all, angelicin appears to be a promising compound for further studies especially on its mechanism and application in therapies for a multitude of

show abstract

Section: In Vivo Experimentsmentioning

confidence: 99%

Section: North America and Chinamentioning

confidence: 99%